Lakefront Biotherapeutics (LKFT) Non-Current Assets (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Non-Current Assets of $364.9 million for Q1 2026, down 36.88% year-over-year from $578.1 million in Q1 2025, and down 4.15% quarter-over-quarter from $380.7 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Non-Current Assets (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Non-Current Assets for 13 consecutive years, with $364.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 36.88% year-over-year to $364.9 million; the TTM figure through Mar 2026 stood at $364.9 million (down 36.88% YoY), while the FY2025 annual figure was $380.7 million, changed 0.43% from the prior year.
- Non-Current Assets retreated to $364.9 million in Q1 2026 per LKFT's latest filing, from $380.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $673.0 million in Q3 2024 and bottomed at $348.4 million in Q4 2023.
- Historically, Non-Current Assets has averaged $488.4 million across 5 years, with a median of $507.6 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 33.92% — and 2025, when it slumped 39.22%.
- Lakefront Biotherapeutics' Non-Current Assets stood at $507.6 million in 2022, then sank by 31.36% to $348.4 million in 2023, then increased by 9.75% to $382.3 million in 2024, then slipped by 0.43% to $380.7 million in 2025, then declined by 4.15% to $364.9 million in 2026.
- Business Quant data shows LKFT's Non-Current Assets at $364.9 million in Q1 2026, $380.7 million in Q4 2025, and $409.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 364.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364.91 Mn |
| Dec 31, 2025 | 380.71 Mn |
| Sep 30, 2025 | 409.04 Mn |
| Jun 30, 2025 | 637.19 Mn |
| Mar 31, 2025 | 578.11 Mn |
| Dec 31, 2024 | 382.34 Mn |
| Sep 30, 2024 | 672.96 Mn |
| Mar 31, 2024 | 624.56 Mn |
| Dec 31, 2023 | 348.39 Mn |
| Sep 30, 2023 | 539.12 Mn |
| Mar 31, 2023 | 511.85 Mn |
| Dec 31, 2022 | 507.57 Mn |
| Mar 31, 2022 | 392.39 Mn |
| Dec 31, 2021 | 379.00 Mn |
| Jun 30, 2021 | 362.63 Mn |
| Dec 31, 2020 | 415.37 Mn |
| Jun 30, 2020 | 252.85 Mn |
| Mar 31, 2020 | 234.19 Mn |
| Dec 31, 2019 | 100.73 Mn |
| Sep 30, 2019 | 223.37 Mn |